EnLiven Therapeutics, Inc.

Organization

Boulder, CO, US

Organizations

Please log in for detailed analytics

Patents Grantslast 30 patents

Information Patent Grant
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
- Patent number 11,807,649
- Issue date Nov 7, 2023
- EnLiven Therapeutics, Inc.
- Joseph P. Lyssikatos
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Please log in for detailed analytics

Patents Applicationslast 30 patents

Information Patent Application
LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2
- Publication number 20240116921
- Publication date Apr 11, 2024
- EnLiven Therapeutics, Inc.
- Joseph P. LYSSIKATOS
- C07 - ORGANIC CHEMISTRY
Information Patent Application
7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES
- Publication number 20240043420
- Publication date Feb 8, 2024
- EnLiven Therapeutics, Inc.
- Joseph P. LYSSIKATOS
- C07 - ORGANIC CHEMISTRY
Information Patent Application
FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
- Publication number 20230382923
- Publication date Nov 30, 2023
- EnLiven Therapeutics, Inc.
- Joseph P. LYSSIKATOS
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
- Publication number 20230265098
- Publication date Aug 24, 2023
- EnLiven Therapeutics, Inc.
- Joseph P. LYSSIKATOS
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
- Publication number 20230159557
- Publication date May 25, 2023
- EnLiven Therapeutics, Inc.
- Joseph P. LYSSIKATOS
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KIN...
- Publication number 20230130724
- Publication date Apr 27, 2023
- EnLiven Therapeutics, Inc.
- Joseph P. LYSSIKATOS
- C07 - ORGANIC CHEMISTRY
Information Patent Application
5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KIN...
- Publication number 20230065635
- Publication date Mar 2, 2023
- EnLiven Therapeutics, Inc.
- Joseph P. LYSSIKATOS
- C07 - ORGANIC CHEMISTRY

EnLiven Therapeutics, Inc.

Organization

Patents Grantslast 30 patents

Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

Patents Applicationslast 30 patents

LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2

7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES

FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2

ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2

FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2

5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KIN...

5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KIN...